Description: Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities in Canada and internationally. Its natural psilocybin is used for the long-term treatment of psychological trauma and its mental health consequences. The company also engages in developing therapeutic, hallucinogenic and subhallucinogenic dosing, and treatment protocols for the treatment of anxiety, depression, PTSD, grief, and bereavement. In addition, it focuses on the development of over-the-counter IP protected nutraceutical products for mental wellbeing. The company has a collaboration agreement with Scientific Research Council of Jamaica for psilocybin product development. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
Home Page: www.psyence.com
200 Bay Street
Toronto,
ON
M5J 2J1
Canada
Phone:
416 477 1708
Officers
| Name | Title |
|---|---|
| Mr. Jody Aufrichtig | Co-Founder & Exec. Chairman |
| Dr. Neil Maresky M.D. | CEO & Director |
| Mr. Alan Mark Friedman B.Com., Bcomm, Bproc Law | Co-Founder & Director |
| Mr. Warwick Corden-Lloyd | CFO & Corp. Sec. |
| Dr. Amza Ali M.D. | Director & Chief Medical Officer |
| Mr. Mike Dacks | Chief Operating Officer |
| Dr. Justin Grant M.B.A., Ph.D., MBA | Chief Scientific Officer |
| Ms. Taryn Vos | Gen. Counsel |
| Ms. Mary-Elizabeth Gifford | Exec. VP of Public Affairs & Corp. Social Responsibility |
| Dr. Dingle Spence B.Sc., M.D., MBBS | Chief Medical Officer of Psyence Jamaica |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.926 |
| Price-to-Sales TTM: | 1358.7928 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |